Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer

Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer

Zhiyu Wang, Aimin Zang, Yaning Wei, Lin An, Dan Hong, Yan Shi, Jingnan Zhang, Shenyong Su, Guotao Fang Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, People’s Republic of ChinaCorrespond...

Full description

Bibliographic Details
Main Authors:	Wang Z, Zang A, Wei Y, An L, Hong D, Shi Y, Zhang J, Su S, Fang G
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-03-01
Series:	Drug Design, Development and Therapy
Subjects:	colorectal cancer combination therapy lipid-polymer hybrid nanoparticles hyaluronic acid irinotecan
Online Access:	https://www.dovepress.com/hyaluronic-acid-capped-irinotecan-and-gene-co-loaded-lipid-polymer-hyb-peer-reviewed-article-DDDT

Similar Items

β-lactoglobulin-irinotecan inclusion complex as a new targeted nanocarrier for colorectal cancer cells
by: Nooshin Bijari, et al.
Published: (2019-01-01)

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008-09-01)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
by: Jiao-Ren Huang, et al.
Published: (2019-02-01)

Irinotecan-Induced Dysarthria
by: Albertine J. Dressel, et al.
Published: (2012-01-01)

Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy
by: Gao Z, et al.
Published: (2017-09-01)

Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
by: I. Grivicich, et al.
Published: (2001-09-01)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
by: Dorte Lisbet Nielsen, et al.
Published: (2017-09-01)

Irinotecan in the treatment of colorectal cancer. A literature review
by: V. A. Ivanov, et al.
Published: (2017-04-01)

Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know
by: Roberto Iezzi, et al.
Published: (2020-01-01)

Influence of lipid concentration on encapsulation and particle size in the development of liposomal irinotecan
by: A. V. Stadnichenko, et al.
Published: (2017-04-01)

Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer
by: Wang D, et al.
Published: (2018-11-01)

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010-11-01)

Novel pharmacogenomic markers of irinotecan-induced severe toxicity in metastatic colorectal cancer patients
by: Chen, Siwen Sylvialin
Published: (2015)

FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
by: N. V. Dobrova, et al.
Published: (2018-02-01)

Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2018-11-01)

Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial
by: Pasquale F. Innominato, et al.
Published: (2020-06-01)

Effect of Irinotecan Combined with Cetuximab on Liver Function in Patients with Advanced Colorectal Cancer with Liver Metastases
by: Yan Liang, et al.
Published: (2016-01-01)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
by: Jesper Andreas Palshof, et al.
Published: (2020-07-01)

LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan
by: Elham Fakhr, et al.
Published: (2021-11-01)

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment
by: Diego Tosi, et al.
Published: (2018-08-01)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01)

Régulation de l'inactivation intratumorale de l'agent antinéoplasique irinotécan par un mécanisme épigénétique
by: Gagnon, Jean-François
Published: (2006)

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
by: Zhuo-Xun Wu, et al.
Published: (2021-02-01)

Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2019-12-01)

Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer
by: Loïg Vaugier, et al.
Published: (2021-01-01)

Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
by: Daniel C. Pan, et al.
Published: (2021-01-01)

Synthesis and Evaluation of a Molecularly Imprinted Polymer for Selective Solid-Phase Extraction of Irinotecan from Human Serum Samples
by: Isabelle Lefebvre-Tournier, et al.
Published: (2012-02-01)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
by: Bekaii-Saab, T., et al.
Published: (2022)

Development of pilot technology for liposomal irinotecan production
by: O. V. Stadnichenko, et al.
Published: (2018-08-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)

Particle and Gel Characterization of Irinotecan-Loaded Double-Reverse Thermosensitive Hydrogel
by: Fakhar ud Din, et al.
Published: (2021-02-01)

Rôle de la voie de glucuronidation dans la susceptibilité et le traitement du cancer colorectal
by: Girard, Hugo
Published: (2008)

A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer
by: Janina Hesse, et al.
Published: (2021-01-01)

Antiproliferative Effects of Hop-derived Prenylflavonoids and Their Influence on the Efficacy of Oxaliplatine, 5-fluorouracil and Irinotecan in Human ColorectalC Cells
by: Martin Ambrož, et al.
Published: (2019-04-01)

Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration
by: Fakhar ud Din, et al.
Published: (2017-01-01)

Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
by: Mateusz Kciuk, et al.
Published: (2020-07-01)

Triple combination of irinotecan + oxaliplatin + 5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer: first experience with a new treatment regimen
by: A. D. Darenskaya, et al.
Published: (2018-05-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
by: Alessandro Ottaiano, et al.
Published: (2019-09-01)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
by: Mashiro Okunaka, et al.
Published: (2021-04-01)